153 related articles for article (PubMed ID: 28428051)
41. Maleimide-functionalised PLGA-PEG nanoparticles as mucoadhesive carriers for intravesical drug delivery.
Kaldybekov DB; Filippov SK; Radulescu A; Khutoryanskiy VV
Eur J Pharm Biopharm; 2019 Oct; 143():24-34. PubMed ID: 31419584
[TBL] [Abstract][Full Text] [Related]
42. Effect of botulinum toxin A on urothelial-release of ATP and expression of SNARE targets within the urothelium.
Hanna-Mitchell AT; Wolf-Johnston AS; Barrick SR; Kanai AJ; Chancellor MB; de Groat WC; Birder LA
Neurourol Urodyn; 2015 Jan; 34(1):79-84. PubMed ID: 24167028
[TBL] [Abstract][Full Text] [Related]
43. Confocal laser scanning microscopy of urinary bladder after intravesical instillation of a fluorescent dye.
Koenig F; Knittel J; Schnieder L; George M; Lein M; Schnorr D
Urology; 2003 Jul; 62(1):158-61. PubMed ID: 12837458
[TBL] [Abstract][Full Text] [Related]
44. Cell-penetrating peptide-doxorubicin conjugate loaded NGR-modified nanobubbles for ultrasound triggered drug delivery.
Lin W; Xie X; Deng J; Liu H; Chen Y; Fu X; Liu H; Yang Y
J Drug Target; 2016; 24(2):134-46. PubMed ID: 26176270
[TBL] [Abstract][Full Text] [Related]
45. Specific binding, stimulation of rodent urinary bladder epithelial ornithine decarboxylase, and induction of transitional cell hyperplasia by the skin tumor promoter 12-O-tetradecanoylphorbol-13-acetate.
Verma AK; Ertürk E; Bryan GT
Cancer Res; 1983 Dec; 43(12 Pt 1):5964-71. PubMed ID: 6315223
[TBL] [Abstract][Full Text] [Related]
46. Lectin bioconjugates trigger urothelial cytoinvasion--a glycotargeted approach for improved intravesical drug delivery.
Neutsch L; Eggenreich B; Herwig E; Marchetti-Deschmann M; Allmaier G; Gabor F; Wirth M
Eur J Pharm Biopharm; 2012 Oct; 82(2):367-75. PubMed ID: 22889683
[TBL] [Abstract][Full Text] [Related]
47. Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer.
Martin DT; Steinbach JM; Liu J; Shimizu S; Kaimakliotis HZ; Wheeler MA; Hittelman AB; Mark Saltzman W; Weiss RM
Mol Cancer Ther; 2014 Jan; 13(1):71-81. PubMed ID: 24222663
[TBL] [Abstract][Full Text] [Related]
48. Bioadhesive drug delivery system using glyceryl monooleate for the intravesical administration of paclitaxel.
Lee SJ; Kim SW; Chung H; Park YT; Choi YW; Cho YH; Yoon MS
Chemotherapy; 2005 Oct; 51(6):311-8. PubMed ID: 16224181
[TBL] [Abstract][Full Text] [Related]
49. Mucopenetration and biocompatibility of polydopamine surfaces for delivery in an Ex Vivo porcine bladder.
Poinard B; Lam SAE; Neoh KG; Kah JCY
J Control Release; 2019 Apr; 300():161-173. PubMed ID: 30853526
[TBL] [Abstract][Full Text] [Related]
50. Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response.
Kavoussi LR; Brown EJ; Ritchey JK; Ratliff TL
J Clin Invest; 1990 Jan; 85(1):62-7. PubMed ID: 2404029
[TBL] [Abstract][Full Text] [Related]
51. [Influence of leakage of the bladder mucosa on the results of external ureterovesicoplasty (author's transl)].
Chiari R; Gilch W
Urologe A; 1978 Sep; 17(5):303-7. PubMed ID: 706008
[TBL] [Abstract][Full Text] [Related]
52. Mechanisms and strategies to enhance penetration during intravesical drug therapy for bladder cancer.
Zhang P; Wu G; Zhang D; Lai WF
J Control Release; 2023 Feb; 354():69-79. PubMed ID: 36603810
[TBL] [Abstract][Full Text] [Related]
53. Cell-penetrating peptide-based nanovehicles potentiate lymph metastasis targeting and deep penetration for anti-metastasis therapy.
Hu H; Wang J; Wang H; Tan T; Li J; Wang Z; Sun K; Li Y; Zhang Z
Theranostics; 2018; 8(13):3597-3610. PubMed ID: 30026869
[TBL] [Abstract][Full Text] [Related]
54. Tumor vascular targeted delivery of polymer-conjugated adenovirus vector for cancer gene therapy.
Yao X; Yoshioka Y; Morishige T; Eto Y; Narimatsu S; Kawai Y; Mizuguchi H; Gao JQ; Mukai Y; Okada N; Nakagawa S
Mol Ther; 2011 Sep; 19(9):1619-25. PubMed ID: 21673661
[TBL] [Abstract][Full Text] [Related]
55. Glioma Dual-Targeting Nanohybrid Protein Toxin Constructed by Intein-Mediated Site-Specific Ligation for Multistage Booster Delivery.
Chen Y; Zhang M; Jin H; Li D; Xu F; Wu A; Wang J; Huang Y
Theranostics; 2017; 7(14):3489-3503. PubMed ID: 28912890
[TBL] [Abstract][Full Text] [Related]
56. In vivo evaluation of mucoadhesive nanoparticulate docetaxel for intravesical treatment of non-muscle-invasive bladder cancer.
Mugabe C; Matsui Y; So AI; Gleave ME; Baker JH; Minchinton AI; Manisali I; Liggins R; Brooks DE; Burt HM
Clin Cancer Res; 2011 May; 17(9):2788-98. PubMed ID: 21357680
[TBL] [Abstract][Full Text] [Related]
57. Expression of drug transporters and drug metabolizing enzymes in the bladder urothelium in man and affinity of the bladder spasmolytic trospium chloride to transporters likely involved in its pharmacokinetics.
Bexten M; Oswald S; Grube M; Jia J; Graf T; Zimmermann U; Rodewald K; Zolk O; Schwantes U; Siegmund W; Keiser M
Mol Pharm; 2015 Jan; 12(1):171-8. PubMed ID: 25466967
[TBL] [Abstract][Full Text] [Related]
58. Intravesical delivery of small activating RNA formulated into lipid nanoparticles inhibits orthotopic bladder tumor growth.
Kang MR; Yang G; Place RF; Charisse K; Epstein-Barash H; Manoharan M; Li LC
Cancer Res; 2012 Oct; 72(19):5069-79. PubMed ID: 22869584
[TBL] [Abstract][Full Text] [Related]
59. Achieving highly efficient gene transfer to the bladder by increasing the molecular weight of polymer-based nanoparticles.
Li G; He S; Schätzlein AG; Weiss RM; Martin DT; Uchegbu IF
J Control Release; 2021 Apr; 332():210-224. PubMed ID: 33607176
[TBL] [Abstract][Full Text] [Related]
60. Urothelial permeability of the isolated whole bladder.
Tammela T; Wein AJ; Monson FC; Levin RM
Neurourol Urodyn; 1993; 12(1):39-47. PubMed ID: 8481729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
